Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Gupta, Priyanka ^a   Cairns, Murray J ^b   Saksena, Nitin K ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; miRNA; mRNA

Indexed keywords

ALPHA INTERFERON; LET 7 G; MICRORNA; MICRORNA 101; MICRORNA 122; MICRORNA 139; MICRORNA 17; MICRORNA 192; MICRORNA 21; MICRORNA 215; MICRORNA 221; MICRORNA 222; MICRORNA 29; MICRORNA 30D; MICRORNA 491; MICRORNA 92; MITOGEN ACTIVATED PROTEIN KINASE P38; RIBAVIRIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

BIOGENESIS; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MIGRATION; CHRONIC LIVER DISEASE; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC ENHANCEMENT; HEPATITIS; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; INTERACTIONS WITH RNA; LIFE CYCLE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; NONHUMAN; ONCOGENE C MYC; PATHOPHYSIOLOGY; QUANTITATIVE ANALYSIS; REVIEW; RNA PROCESSING; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRUS ONCOGENE; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; MICRORNAS; RNA INTERFERENCE;

EID: 84898418858     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-64     Document Type: Review

References (145)

1. Fact sheet No 164. http://www.who.int/mediacentre/factsheets/fs164/en/
2. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T, Clin Infect Dis 2006 43 1154 1159 10.1086/507640 17029134 (Pubitemid 44632798)
3. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF, Eur J Gastroenterol Hepatol 2010 22 157 166 10.1097/MEG.0b013e328330a8e8 19734798
4. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Micallef JM, Kaldor JM, Dore GJ, J Viral Hepat 2006 13 34 41 10.1111/j.1365-2893.2005.00651.x 16364080
5. management of hepatitis C virus infection. EASL Clinical Practice Guidelines, J Hepatol 2011 55 245 264 21371579
6. The natural history of hepatitis C. Afdhal NH, Semin Liver Dis 2004 24 Suppl 2 3 8 (Pubitemid 39180700)
7. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K, Health Technol Assess 2007 11 1 206
8. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Miglioresi L, Bacosi M, Russo F, Patrizi F, Saccenti P, Ursitti A, Angelis AD, Ricci GL, Hepatol Res 2003 27 253 259 10.1016/S1386-6346(03)00269-9 14662112 (Pubitemid 38009009)
9. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Haussinger D, Smith CI, Lin A, Pappas SC, J Hepatol 2002 37 500 506 10.1016/S0168-8278(02)00211-8 12217604
10. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Sjogren MH, Sjogren R Jr, Lyons MF, Ryan M, Santoro J, Smith C, Reddy KR, Bonkovsky H, Huntley B, Faris-Young S, Dig Dis Sci 2007 52 1540 1547 10.1007/s10620-007-9757-9 17406822 (Pubitemid 46776512)
11. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, Hepatitis Interventional Therapy Group, N Engl J Med 1998 339 1485 1492 10.1056/NEJM199811193392101 9819446 (Pubitemid 28543496)
12. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438 (Pubitemid 38167318)
13. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Lee RC, Feinbaum RL, Ambros V, Cell 1993 75 843 854 10.1016/0092-8674(93)90529-Y 8252621 (Pubitemid 24014542)
14. The diverse functions of microRNAs in animal development and disease. Kloosterman WP, Plasterk RH, Dev Cell 2006 11 441 450 10.1016/j.devcel.2006.09. 009 17011485 (Pubitemid 44430905)
15. microRNA functions. Bushati N, Cohen SM, Annu Rev Cell Dev Biol 2007 23 175 205 10.1146/annurev.cellbio.23.090506.123406 17506695
16. Most mammalian mRNAs are conserved targets of microRNAs. Friedman RC, Farh KK, Burge CB, Bartel DP, Genome Res 2009 19 92 105 18955434
17. microRNAs: tiny regulators with great potential. Ambros V, Cell 2001 107 823 826 10.1016/S0092-8674(01)00616-X 11779458 (Pubitemid 34084973)
18. Identification of novel genes coding for small expressed RNAs. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T, Science 2001 294 853 858 10.1126/science.1064921 11679670 (Pubitemid 33032103)
19. New microRNAs from mouse and human. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T, RNA 2003 9 175 179 10.1261/rna.2146903 12554859 (Pubitemid 36206285)
20. Vertebrate microRNA genes. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP, Science 2003 299 1540 10.1126/science.1080372 12624257 (Pubitemid 36297696)
21. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. Cai X, Hagedorn CH, Cullen BR, RNA 2004 10 1957 1966 10.1261/rna.7135204 15525708 (Pubitemid 39557833)
22. MicroRNA genes are transcribed by RNA polymerase II. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN, EMBO J 2004 23 4051 4060 10.1038/sj.emboj. 7600385 15372072 (Pubitemid 39472426)
23. The nuclear RNase III Drosha initiates microRNA processing. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN, Nature 2003 425 415 419 10.1038/nature01957 14508493 (Pubitemid 37187272)
24. Processing of primary microRNAs by the Microprocessor complex. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ, Nature 2004 432 231 235 10.1038/nature03049 15531879 (Pubitemid 39545854)
25. The Microprocessor complex mediates the genesis of microRNAs. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R, Nature 2004 432 235 240 10.1038/nature03120 15531877 (Pubitemid 39545855)
26. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Yi R, Qin Y, Macara IG, Cullen BR, Genes Dev 2003 17 3011 3016 10.1101/gad.1158803 14681208 (Pubitemid 38040764)
27. Nuclear export of microRNA precursors. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U, Science 2004 303 95 98 10.1126/science.1090599 14631048 (Pubitemid 38055779)
28. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R, Nature 2005 436 740 744 10.1038/nature03868 15973356 (Pubitemid 41117280)
29. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Hammond SM, Bernstein E, Beach D, Hannon GJ, Nature 2000 404 293 296 10.1038/35005107 10749213 (Pubitemid 30163547)
30. Argonaute2 is the catalytic engine of mammalian RNAi. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ, Science 2004 305 1437 1441 10.1126/science.1102513 15284456 (Pubitemid 39167657)
31. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T, Mol Cell 2004 15 185 197 10.1016/j.molcel.2004.07.007 15260970 (Pubitemid 38950966)
32. Specificity of microRNA target selection in translational repression. Doench JG, Sharp PA, Genes Dev 2004 18 504 511 10.1101/gad.1184404 15014042 (Pubitemid 38372808)
33. Context-specific microRNA function in developmental complexity. Carroll AP, Tooney PA, Cairns MJ, J Mol Cell Biol 2013 5 73 84 10.1093/jmcb/mjt004 23362311
34. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P, Science 2005 309 1577 1581 10.1126/science.1113329 16141076 (Pubitemid 41266486)
35. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Banaudha K, Kaliszewski M, Korolnek T, Florea L, Yeung ML, Jeang KT, Kumar A, Hepatology 2011 53 53 61 10.1002/hep.24016 20967756
36. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB, J Virol 2012 86 10221 10225 10.1128/JVI.00882-12 22787204
37. Interferon modulation of cellular microRNAs as an antiviral mechanism. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M, Nature 2007 449 919 922 10.1038/nature06205 17943132 (Pubitemid 47598616)
38. Let-7b is a novel regulator of hepatitis C virus replication. Cheng JC, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD, Cell Mol Life Sci 2012 69 2621 2633 10.1007/s00018-012-0940-6 22391672
39. Regulation of the hepatitis C virus genome replication by miR-199a. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K, J Hepatol 2009 50 453 460 19144437
40. Cellular cofactors affecting hepatitis C virus infection and replication. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM, Proc Natl Acad Sci USA 2007 104 12884 12889 10.1073/pnas.0704894104 17616579 (Pubitemid 47255249)
41. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. Jangra RK, Yi M, Lemon SM, J Virol 2010 84 6615 6625 10.1128/JVI.00417-10 20427538
42. microRNA-122 stimulates translation of hepatitis C virus RNA. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, Junemann C, Niepmann M, EMBO J 2008 27 3300 3310 10.1038/emboj.2008.244 19020517
43. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W, Nat Med 2009 15 31 33 10.1038/nm.1902 19122656
44. Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. Zhang C, Huys A, Thibault PA, Wilson JA, Virology 2012 433 479 488 10.1016/j.virol.2012.08.039 22999255
45. Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Machlin ES, Sarnow P, Sagan SM, Proc Natl Acad Sci U S A 2011 108 3193 3198 10.1073/pnas.1012464108 21220300
46. Enhancer-like interferon responsive sequences of the human and murine (2′-5′) oligoadenylate synthetase gene promoters. Cohen B, Peretz D, Vaiman D, Benech P, Chebath J, EMBO J 1988 7 1411 1419 2457496
47. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Levy DE, Kessler DS, Pine R, Reich N, Darnell JE Jr, Genes Dev 1988 2 383 393 10.1101/gad.2.4.383 3371658
48. Interferon response element of the human gene 6-16. Porter AC, Chernajovsky Y, Dale TC, Gilbert CS, Stark GR, Kerr IM, EMBO J 1988 7 85 92 3359997
49. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Reich N, Evans B, Levy D, Fahey D, Knight E Jr, Darnell JE Jr, Proc Natl Acad Sci U S A 1987 84 6394 6398 10.1073/pnas.84.18.6394 3476954 (Pubitemid 18002807)
50. Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene. Rutherford MN, Hannigan GE, Williams BR, EMBO J 1988 7 751 759 2456211
51. Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation. Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, Koike K, Sci Rep 2012 2 637 22957141
52. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Roberts AP, Lewis AP, Jopling CL, Nucleic Acids Res 2011 39 7716 7729 10.1093/nar/gkr426 21653556
53. Human Ago2 is required for efficient microRNA 122 regulation of hepatitis C virus RNA accumulation and translation. Wilson JA, Zhang C, Huys A, Richardson CD, J Virol 2011 85 2342 2350 10.1128/JVI.02046-10 21177824
54. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Hou W, Bukong TN, Kodys K, Szabo G, Alcohol Clin Exp Res 2013 37 599 608 10.1111/acer.12005 23126531
55. Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM, Proc Natl Acad Sci USA 2013 110 1881 1886 10.1073/pnas.1213515110 23248316
56. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM, J Virol 2008 82 8215 8223 10.1128/JVI.02575-07 18550664
57. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, Kamitani W, Matsuura Y, J Virol 2012 86 1382 1393 10.1128/JVI.06242-11 22114337
58. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, Evans MJ, J Virol 2011 85 12087 12092 10.1128/JVI.05843-11 21917968
59. Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases. Fehr C, Conrad KD, Niepmann M, Cell Cycle 2012 11 277 285 10.4161/cc.11.2.18699 22189820
60. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. Zhang X, Daucher M, Armistead D, Russell R, Kottilil S, PLoS One 2013 8 55733 10.1371/journal.pone.0055733 23418453
61. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. Li S, Duan X, Li Y, Liu B, McGilvray I, Chen L, J Viral Hepat 2014 21 121 128 10.1111/jvh.12131 24383925
62. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S, Liu Y, Wu J, PLoS Pathog 2013 9 1003248 10.1371/journal.ppat.1003248 23633945
63. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hou W, Tian Q, Zheng J, Bonkovsky HL, Hepatology 2010 51 1494 1504 10.1002/hep.23401 20127796
64. Natural course of acute hepatitis C: a long-term prospective study. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, Pastore G, Dig Liver Dis 2003 35 104 113 10.1016/S1590-8658(03)00007- 0 12747629 (Pubitemid 41490321)
65. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M, Hepatology 2008 47 1223 1232 18307259 (Pubitemid 351547908)
66. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K, Oncogene 2006 25 2537 2545 10.1038/sj.onc.1209283 16331254
67. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD, Clin Cancer Res 2008 14 419 427 10.1158/1078-0432.CCR-07-0523 18223217 (Pubitemid 351226109)
68. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M, Cancer Res 2007 67 6092 6099 10.1158/0008-5472.CAN-06-4607 17616664 (Pubitemid 47037488)
69. miR-221 overexpression contributes to liver tumorigenesis. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A, Proc Natl Acad Sci USA 2010 107 264 269 10.1073/pnas. 0907904107 20018759
70. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S, Hepatology 2009 49 1098 1112 10.1002/hep.22749 19173277
71. Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. Peng X, Li Y, Walters KA, Rosenzweig ER, Lederer SL, Aicher LD, Proll S, Katze MG, BMC Genomics 2009 10 373 10.1186/1471-2164-10-373 19671175
72. MicroRNA signatures in human cancers. Calin GA, Croce CM, Nat Rev Cancer 2006 6 857 866 10.1038/nrc1997 17060945 (Pubitemid 44629897)
73. miR-21-mediated tumor growth. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY, Oncogene 2007 26 2799 2803 10.1038/sj.onc.1210083 17072344 (Pubitemid 46663837)
74. MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR, Nature 2005 435 834 838 10.1038/nature03702 15944708 (Pubitemid 40839735)
75. MicroRNA gene expression deregulation in human breast cancer. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM, Cancer Res 2005 65 7065 7070 10.1158/0008-5472.CAN-05-1783 16103053 (Pubitemid 41161233)
76. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, Cole CN, Cancer Res 2007 67 11612 11620 10.1158/0008-5472.CAN-07-5019 18089790
77. Expression profiling identifies microRNA signature in pancreatic cancer. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD, Int J Cancer 2007 120 1046 1054 17149698 (Pubitemid 46214304)
78. A microRNA expression signature of human solid tumors defines cancer gene targets. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM, Proc Natl Acad Sci USA 2006 103 2257 2261 10.1073/pnas.0510565103 16461460 (Pubitemid 43271657)
79. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Chan JA, Krichevsky AM, Kosik KS, Cancer Res 2005 65 6029 6033 10.1158/0008-5472.CAN- 05-0137 16024602 (Pubitemid 40994386)
80. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H, Oncogene 2008 27 2128 2136 10.1038/sj.onc.1210856 17968323 (Pubitemid 351485639)
81. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ, Hepatology 2009 49 1595 1601 10.1002/hep.22838 19296468
82. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E, J Biol Chem 2009 284 26533 26546 10.1074/jbc.M109.027466 19633292
83. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T, Gastroenterology 2006 130 2113 2129 10.1053/j.gastro.2006.02.057 16762633 (Pubitemid 43816961)
84. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K, Mol Cell 2010 39 493 506 10.1016/j.molcel.2010. 07.023 20797623
85. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T, Gastroenterology 2007 133 647 658 10.1053/j.gastro.2007.05.022 17681183 (Pubitemid 47187346)
86. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J, Hepatology 2008 47 1955 1963 10.1002/hep.22256 18433021 (Pubitemid 351952843)
87. The role of microRNAs in liver cancer progression. Huang S, He X, Br J Cancer 2011 104 235 240 10.1038/sj.bjc.6606010 21102580
88. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB, J Biol Chem 2006 281 4816 4822 10.1074/jbc.M508300200 16371366 (Pubitemid 43847743)
89. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, Yan L, Malhotra A, Vatner D, Abdellatif M, Mol Biol Cell 2008 19 3272 3282 10.1091/mbc.E08-02-0159 18508928
90. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Connolly EC, Van Doorslaer K, Rogler LE, Rogler CE, Mol Cancer Res 2010 8 691 700 10.1158/1541-7786.MCR-09-0465 20460403
91. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Liu AX, Rane N, Liu JP, Prendergast GC, Mol Cell Biol 2001 21 6906 6912 10.1128/MCB.21.20.6906-6912.2001 11564874 (Pubitemid 32911251)
92. Regulation of miRNA-21 by reactive oxygen species-activated ERK/NF-kappaB in arsenite-induced cell transformation. Ling M, Li Y, Xu Y, Pang Y, Shen L, Jiang R, Zhao Y, Yang X, Zhang J, Zhou J, Wang X, Liu Q, Free Radic Biol Med 2012 52 1508 1518 10.1016/j.freeradbiomed.2012.02.020 22387281
93. MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4). Itani S, Kunisada T, Morimoto Y, Yoshida A, Sasaki T, Ito S, Ouchida M, Sugihara S, Shimizu K, Ozaki T, J Cancer Res Clin Oncol 2012 138 1501 1509 10.1007/s00432-012-1223-1 22526161
94. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY, Cell Res 2008 18 350 359 10.1038/cr.2008.24 18270520 (Pubitemid 351333899)
95. Signalling in osteoclasts and the role of Fos/AP1 proteins. Wagner EF, Matsuo K, Ann Rheum Dis 2003 62 Suppl 2 i83 ii85 14532157
96. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L, Stapleton G, Eur J Cancer 2000 36 1640 1648 10.1016/S0959-8049(00)00175-1 10959050 (Pubitemid 30616368)
97. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K, Iba H, J Mol Biol 2008 378 492 504 10.1016/j.jmb.2008. 03.015 18384814
98. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Tannapfel A, Grund D, Katalinic A, Uhlmann D, Kockerling F, Haugwitz U, Wasner M, Hauss J, Engeland K, Wittekind C, Int J Cancer 2000 89 350 355 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0. CO;2-3 10956409 (Pubitemid 30620288)
99. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M, Oncogene 2008 27 5651 5661 10.1038/onc.2008.178 18521080
100. MicroRNA involvement in hepatocellular carcinoma. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M, J Cell Mol Med 2008 12 2189 2204 10.1111/j.1582-4934.2008.00533.x 19120703
101. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M, Clin Cancer Res 2009 15 5073 5081 10.1158/1078-0432.CCR-09-0092 19671867
102. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N, Clin Cancer Res 2010 16 867 875 10.1158/1078-0432.CCR-09-1840 20103675
103. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A, Cancer Cell 2008 13 272 286 10.1016/j.ccr.2008.02.013 18328430 (Pubitemid 351318375)
104. A microRNA polycistron as a potential human oncogene. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM, Nature 2005 435 828 833 10.1038/nature03552 15944707 (Pubitemid 40839734)
105. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE, Am J Pathol 2008 173 856 864 10.2353/ajpath.2008.080096 18688024
106. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, Sun S, Hepatology 2010 51 1614 1623 10.1002/hep.23566 20209605
107. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Yao J, Liang L, Huang S, Ding J, Tan N, Zhao Y, Yan M, Ge C, Zhang Z, Chen T, Wan D, Yao M, Li J, Gu J, He X, Hepatology 2010 51 846 856 20054866
108. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, Hikita H, Hiramatsu N, Kanto T, Hayashi N, Takehara T, Biochem Biophys Res Commun 2011 412 92 97 10.1016/j.bbrc.2011.07.049 21802413
109. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K, J Biol Chem 2009 284 32015 32027 10.1074/jbc.M109.016774 19726678
110. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS, Oncogene 2009 28 3526 3536 10.1038/onc.2009.211 19617899
111. miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Wu X, Wu S, Tong L, Luan T, Lin L, Lu S, Zhao W, Ma Q, Liu H, Zhong Z, Scand J Gastroenterol 2009 44 1332 1339 10.3109/00365520903215305 19891584
112. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L, Cancer Res 2009 69 5761 5767 10.1158/0008-5472.CAN-08-4797 19584283
113. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP, Hepatology 2009 49 1571 1582 10.1002/hep.22806 19296470
114. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T, Hepatology 2011 53 209 218 10.1002/hep.23922 20890893
115. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM, Cancer Res 2009 69 1135 1142 19155302
116. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM, Hepatology 2010 51 836 845 20041405
117. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4. Zekri AR, Bahnassy AA, Abdel-Wahab SA, Khafagy MM, Loutfy SA, Radwan H, Shaarawy SM, J Gastroenterol Hepatol 2009 24 416 428 10.1111/j.1440-1746.2008.05699.x 19054267
118. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V, J Hepatol 2006 44 151 157 10.1016/j.jhep.2005.09.010 16289418 (Pubitemid 41772529)
119. Bcl-2 family proteins and cancer. Yip KW, Reed JC, Oncogene 2008 27 6398 6406 10.1038/onc.2008.307 18955968
120. BCL-2 family antagonists for cancer therapy. Lessene G, Czabotar PE, Colman PM, Nat Rev Drug Discov 2008 7 989 1000 10.1038/nrd2658 19043450
121. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R, Leukemia 2005 19 1248 1252 10.1038/sj.leu.2403784 15902294 (Pubitemid 40946011)
122. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, Sun Z, Wei L, Zheng X, Hepatology 2009 49 1194 1202 10.1002/hep.22757 19133651
123. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng IO, Gastroenterology 2011 140 322 331 10.1053/j.gastro.2010.10.006 20951699
124. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Wong CC, Wong CM, Tung EK, Man K, Ng IO, Hepatology 2009 49 1583 1594 10.1002/hep.22836 19205033
125. Hsa-let-7 g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Lan FF, Wang H, Chen YC, Chan CY, Ng SS, Li K, Xie D, He ML, Lin MC, Kung HF, Int J Cancer 2011 128 319 331 10.1002/ijc.25336 20309945
126. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA, Nature 1994 368 753 756 10.1038/368753a0 8152487 (Pubitemid 24153417)
127. Let-7 g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY, Wang XW, J Hepatol 2010 52 690 697 10.1016/j.jhep.2009.12.025 20338660
128. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, Lancet 2001 358 958 965 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
129. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J, J Hepatol 2006 44 97 103 10.1016/j.jhep.2005.10.003 16290907 (Pubitemid 41772522)
130. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J, Hepatology 2003 38 645 652 12939591 (Pubitemid 37052151)
131. Side effects of therapy of hepatitis C and their management. Fried MW, Hepatology 2002 36 237 S244 12407599
132. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J, N Engl J Med 2002 347 975 982 10.1056/NEJMoa020047 12324553
133. Therapy of hepatitis C: from empiricism to eradication. Pawlotsky JM, Hepatology 2006 43 207 S220 10.1002/hep.21064 16447262
134. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM, J Hepatol 2006 44 411 421 10.1016/j.jhep.2005.12.001 16364491 (Pubitemid 43069225)
135. Sequence-specific inhibition of small RNA function. Hutvagner G, Simard MJ, Mello CC, Zamore PD, PLoS Biol 2004 2 98 10.1371/journal.pbio.0020098 15024405 (Pubitemid 39234504)
136. Silencing of microRNAs in vivo with 'antagomirs'. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M, Nature 2005 438 685 689 10.1038/nature04303 16258535 (Pubitemid 41740580)
137. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL, Gastroenterology 2007 133 1166 1174 10.1053/j.gastro.2007.08.002 17919492 (Pubitemid 47494462)
138. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP, Cell Metab 2006 3 87 98 10.1016/j.cmet.2006.01.005 16459310
139. Potent inhibition of microRNA in vivo without degradation. Davis S, Propp S, Freier SM, Jones LE, Serra MJ, Kinberger G, Bhat B, Swayze EE, Bennett CF, Esau C, Nucleic Acids Res 2009 37 70 77 10.1093/nar/gkn904 19015151
140. Treatment of HCV Infection by Targeting MicroRNA. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR, New England J of Med 2013 368 1685 1694 10.1056/NEJMoa1209026
141. Dual Role of miR-122 in Molecular Pathogenesis of Viral Hepatitis. Sendi H, Hepat Mon 2012 12 312 314 10.5812/hepatmon.6128 22783341
142. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, Wu E, Ye X, Gao GF, Wang F, Chen Y, Duan Z, Meng S, Hepatology 2012 55 730 741 10.1002/hep.24809 22105316
143. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, Wu F, Liver Int 2012 32 752 760 10.1111/j.1478-3231.2011.02750.x 22276989
144. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Fan CG, Wang CM, Tian C, Wang Y, Li L, Sun WS, Li RF, Liu YG, Oncol Rep 2011 26 1281 1286 21725618
145. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H, Science 2010 327 198 201 10.1126/science.1178178 19965718